Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.34) by 41.18 percent. The company reported quarterly sales of $16.574 million which beat the analyst consensus estimate of $13.768 million by 20.38 percent. This is a 25.00 percent decrease over sales of $22.099 million the same period last year.